知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

172 records (took 0.079 seconds)

    Stably tethered structures of defined compositions with multiple functions or binding specificities
    26.
    发明授权
    Stably tethered structures of defined compositions with multiple functions or binding specificities 有权
    具有多种功能或结合特异性的定义组合物的稳定的束缚结构

    公开(公告)号：US09540435B2

    公开(公告)日：2017-01-10

    申请号：US14521013

    申请日：2014-10-22

    Applicant: IBC Pharmaceuticals, Inc.

    Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  William J. McBride ,  Edmund A. Rossi

    IPC: A61K47/48 ,  A61K51/08 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K16/18 ,  A61K39/395 ,  A61K51/10 ,  B82Y5/00 ,  B82Y10/00 ,  B82Y30/00

    CPC classification number: C07K16/18 ,  A61K39/395 ,  A61K47/65 ,  A61K47/6853 ,  A61K51/088 ,  A61K51/1048 ,  B82Y5/00 ,  B82Y10/00 ,  B82Y30/00 ,  C07K16/283 ,  C07K16/3007 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/70

    Abstract: The present invention concerns stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound.

    Abstract translation: 本发明涉及具有多种功能和/或结合特异性的稳定的具有限定组合物的束缚结构。 具体实施方案涉及稳定的包含第一单体的同二聚体的束缚结构，其包含连接到第一前体的二聚化和对接结构域，以及包含连接到第二前体的锚定结构域的第二单体。 第一和第二前体实际上可以是任何分子或结构，例如抗体，抗体片段，抗体类似物或模拟物，适体，结合肽，结合蛋白片段，蛋白质或其他分子的已知配体，酶，可检测标记或标签， 治疗剂，毒素，药物，细胞因子，白介素，干扰素，放射性同位素，蛋白质，肽，肽模拟物，多核苷酸，RNAi，寡糖，天然或合成聚合物质，纳米颗粒，量子点，有机或无机化合物等。 组合物提供了一种简单，易于纯化的方式来获得连接到任何单体化合物或任何三元化合物上的任何二元化合物。

    HUMANIZED ANTI-CEACAM5 ANTIBODY AND USES THEREOF
    29.
    发明申请
    HUMANIZED ANTI-CEACAM5 ANTIBODY AND USES THEREOF 审中-公开
    人类抗-CACACAM5抗体及其用途

    公开(公告)号：US20150125386A1

    公开(公告)日：2015-05-07

    申请号：US14515765

    申请日：2014-10-16

    Applicant: IMMUNOMEDICS, INC.

    Inventor： Hans J. Hansen ,  David M. Goldenberg

    IPC: C07K16/18 ,  A61K47/48 ,  A61K51/04

    CPC classification number: C07K16/3007 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6853 ,  A61K47/6863 ,  A61K51/1048 ,  A61K2039/505 ,  C07K2317/24

    Abstract: The present invention concerns compositions and methods of use of a humanized Class III anti-CEA antibody, comprising the heavy and light amino acid sequences SEQ ID NO:1 and SEQ ID NO:2. The antibody is effective to treat CEACAM5-expressing tumors, either alone or in combination with one or more therapeutic agents. Drug conjugated Class III anti-CEA antibodies, such as SN-38 or P2PDox immunoconjugates, are particularly efficacious. Surprisingly, the antibody-drug conjugates (ADCs) exhibit high anti-cancer efficacy, while exhibiting low levels of systemic toxicity that are readily treated with standard amelioration techniques. Antibodies and/or immunoconjugates comprising the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2 are surprisingly efficacious for therapy of solid tumors, even when the tumor has proven resistant to standard anti-cancer therapies.

    Abstract translation: 本发明涉及使用人源化III类抗CEA抗体的组合物和方法，其包含重和轻氨基酸序列SEQ ID NO：1和SEQ ID NO：2。 该抗体单独或与一种或多种治疗剂组合可有效治疗表达CEACAM5的肿瘤。 药物偶联的III类抗CEA抗体，如SN-38或P2PDox免疫缀合物，是特别有效的。 令人惊讶的是，抗体 - 药物偶联物（ADC）表现出高的抗癌功效，同时表现出低水平的全身毒性，容易用标准改良技术处理。 包含氨基酸序列SEQ ID NO：1和SEQ ID NO：2的抗体和/或免疫偶联物对于治疗实体瘤是惊人的，即使当肿瘤已被证实对标准抗癌疗法具有抗性时。

Patent Agency Ranking